Market Cap
$282.3M
FULC
Fulcrum Therapeutics, Inc.
$3.67 ▼ -0.27%
Prev close $3.68Market cap$282.3M
12-mo target$3.67 (-0.1%)
Insider Buying Cluster (2 insiders)High Impact Filing (7/10)30 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on FULC right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$174.0M
Inst. Activity
30 buys / 17 sells
Insider Activity
$1.5M buy / $389.6K sell
Insider Net $
$1.1M
Social Sentiment
33° Cool
SEC Reports
9
Press Releases
2
Price chart 30d -4.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 9, 2026 short_volume
Sep 2, 2026 SEC Short Volume: FULC — 65.6% short (0.4M / 0.6M)
Short: 386,813 | Exempt: 0 | TRF Vol: 589,709 | Short Ratio: 65.6% | Off-exchange volume (dark pool
Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a reverse merger with privately-held Slate Medicines
S-4 — Impact 7/10
Fulcrum Therapeutics (FULC) filed a Rule 425 transcript of a joint conference call with Slate Medicines, confirming the
425 — Impact 7/10
Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Fulcrum will acquire Sl
425 — Impact 8/10
Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum stockh
Impact 8/10
Jul 17, 2026 Insider
TANG KEVIN bought 50,945 shares
10%+ Owner @ $3.52 ($179.3K)
Jul 16, 2026 Insider
TANG KEVIN bought 116,671 shares
10%+ Owner @ $3.56 ($415.3K)
Jul 15, 2026 Insider
TANG KEVIN bought 107,377 shares
10%+ Owner @ $3.56 ($382.3K)
Analyst ratings buy % -100.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 3, 2026 | JP Morgan | DOWNGRADE | Underweight | 55% |
| Jun 2, 2026 | Stifel | DOWNGRADE | Hold | 54% |
| Jun 2, 2026 | Piper Sandler | DOWNGRADE | Underweight | 54% |
| Jun 2, 2026 | Truist Securities | DOWNGRADE | Hold | 55% |
| Jun 2, 2026 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Jun 2, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 0 | 7 | 2 | 2 | 0% | |
| Aug 1, 2026 | 0 | 0 | 7 | 3 | 2 | 0% | |
| Jul 1, 2026 | 0 | 0 | 7 | 4 | 2 | 0% | |
| Jun 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| May 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| Apr 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| Mar 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% | |
| Feb 1, 2026 | 5 | 8 | 2 | 1 | 0 | 81% |
Price targets
Where 3 covering analysts think FULC trades over the next 12 months.
$3.67 -0.1% upside Hold
Current$3.67 Low$3.00 Median$4.00 High$4.00 3 analysts
$3.00$4.00
Analyst rating Hold· 3.2/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
33°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 3 bullish, 2 bearish, 3 mixed, 1 neutral · avg impact 6.1/10.Plus 2 press releases.
BEARISHS-47/10
Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a reverse merger with privately-
Sep 2, 2026
BEARISH4257/10
Fulcrum Therapeutics (FULC) filed a Rule 425 transcript of a joint conference call with Slate Medici
Aug 17, 2026
BULLISH4258/10
Fulcrum Therapeutics (FULC) and Slate Medicines announced a definitive merger agreement in which Ful
Aug 17, 2026
BULLISH8-K8/10
Fulcrum Therapeutics (FULC) entered into a definitive merger agreement to acquire Slate Medicines in
Aug 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 9, 2026
short_volume
Short Volume: FULC — 65.6% short (0.4M / 0.6M)
Short: 386,813 | Exempt: 0 | TRF Vol: 589,709 | Short Ratio: 65.6% | Off-exchange volume (dark pool + OTC)
Aug 28, 2026
short_volume
Short Volume: FULC — 64.6% short (0.4M / 0.7M)
Short: 445,260 | Exempt: 0 | TRF Vol: 688,868 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Aug 17, 2026
other
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, Aug. 17, 2026 /PRNewswire/ -- Ademi LLP is investigating Fulcrum (Nasdaq: FULC) for possible breaches of fiduciary duty and other violation
Aug 17, 2026
m_and_a
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics
Aug 5, 2026
earnings_calendar
FULC Q2 2026 Earnings Scheduled — 2026-08-05
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.11 | $-0.13–$-0.08 | 65.6% | +4.0% | 1↑ 0↓ | $0.0B | 2 |
| Next Q | $-0.07 | $-0.08–$-0.05 | 78.5% | -3.4% | 1↑ 0↓ | $0.0B | 2 |
| Current FY | $-0.66 | $-0.81–$-0.51 | 44.4% | +0.2% | 1↑ 1↓ | $0.0B | 3 |
| Next FY | $-0.55 | $-1.46–$-0.01 | 16.5% | -12.2% | 1↑ 0↓ | $0.0B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.107 | — |
| 7d ago | $-0.111 | +0.004 |
| 30d ago | $-0.111 | +0.004 |
| 60d ago | $-0.153 | +0.047 |
| 90d ago | $-0.178 | +0.071 |
Institutional ownership
Which big funds own FULC (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $174.0M total value (47,432,152 shares) as of 2026-Q2. Top holders: BlackRock,, D., CITADEL. Net buying activity: 30 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 8,824,259 | $32.3M | 18.6% | ADD +63.7% |
| D. E. Shaw & Co., Inc. | 3,044,385 | $11.1M | 6.4% | ADD +87.5% |
| CITADEL ADVISORS LLC | 2,704,505 | $9.9M | 5.7% | DOUBLED +109.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,697,216 | $9.9M | 5.7% | — |
| JANE STREET GROUP, LLC | 2,217,498 | $8.1M | 4.7% | DOUBLED +614.4% |
| STATE STREET CORP | 2,037,025 | $7.5M | 4.3% | ADD +31.4% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,000,000 | $7.3M | 4.2% | DOUBLED +400.0% |
| Qube Research & Technologies Ltd | 1,748,467 | $6.4M | 3.7% | ADD +79.4% |
| RENAISSANCE TECHNOLOGIES LLC | 1,647,800 | $6.0M | 3.5% | DOUBLED +12016.2% |
| MILLENNIUM MANAGEMENT LLC | 1,485,803 | $5.4M | 3.1% | DOUBLED +316.8% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 5,390,593 | 8,824,259 | +63.7% | $32.3M |
| D. E. Shaw & Co., Inc. | ADD | 1,623,281 | 3,044,385 | +87.5% | $11.1M |
| CITADEL ADVISORS LLC | DOUBLED | 1,292,486 | 2,704,505 | +109.2% | $9.9M |
| JANE STREET GROUP, LLC | DOUBLED | 310,417 | 2,217,498 | +614.4% | $8.1M |
| STATE STREET CORP | ADD | 1,549,851 | 2,037,025 | +31.4% | $7.5M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 400,000 | 2,000,000 | +400.0% | $7.3M |
| Qube Research & Technologies Ltd | ADD | 974,739 | 1,748,467 | +79.4% | $6.4M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 13,600 | 1,647,800 | +12016.2% | $6.0M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 356,471 | 1,485,803 | +316.8% | $5.4M |
| UBS Group AG | DOUBLED | 315,185 | 1,253,909 | +297.8% | $4.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 22 transactions. Net $1.1M — $1.5M bought, $389.6K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 17, 2026 | TANG KEVIN | 10%+ Owner | BUY | 50,945 | $3.52 | $179.3K |
| Jul 16, 2026 | TANG KEVIN | 10%+ Owner | BUY | 116,671 | $3.56 | $415.3K |
| Jul 15, 2026 | TANG KEVIN | 10%+ Owner | BUY | 107,377 | $3.56 | $382.3K |
| Jul 14, 2026 | TANG KEVIN | 10%+ Owner | BUY | 75,952 | $3.58 | $271.9K |
| Jul 14, 2026 | TANG KEVIN | 10%+ Owner | BUY | 53,651 | $3.56 | $191.0K |
| Jul 13, 2026 | TANG KEVIN | 10%+ Owner | BUY | 12,966 | $3.54 | $45.9K |
| Jun 30, 2026 | Banks Sonja | Director | AWARD | 32,000 | — | — |
| Jun 30, 2026 | Haviland Kate | Director | AWARD | 32,000 | — | — |
| Jun 30, 2026 | Ezekowitz Alan | Director | AWARD | 32,000 | — | — |
| Jun 30, 2026 | Hill Colin | Director | AWARD | 32,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for FULC.
Shares short
7,194,912
Settlement Sep 15, 2026
Change vs prior
+2.5%
Semi-monthly cycle
Days to cover
5.9
At avg daily volume
Of shares outstanding
≈9.4%
Estimate — not % of float
All FULC filing & press-release reports (11)
- S-4 reportSep 2, 2026
- 425 reportAug 17, 2026
- 425 reportAug 17, 2026
- 8-K reportAug 17, 2026
- PRESS-RELEASE reportAug 17, 2026
- 8-K reportAug 10, 2026
- 3 reportJul 16, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportMar 19, 2026